tiprankstipranks
Trending News
More News >

Rafael Holdings CEO Resignation Announced

Story Highlights
  • William Conkling resigned as CEO of Rafael Holdings, effective May 31, 2025.
  • Howard Jonas will assume the CEO role, focusing on clinical developments post-merger with Cyclo Therapeutics.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Rafael Holdings ( (RFL) ) just unveiled an update.

On April 23, 2025, Rafael Holdings announced the resignation of William Conkling as CEO, effective May 31, 2025, with Howard Jonas taking over on June 1, 2025. This leadership change follows the merger with Cyclo Therapeutics, positioning Rafael Holdings as a late-stage clinical biotechnology company. The company is focused on developing treatments for Niemann-Pick Disease Type C1, with the TransportNPC™ Phase 3 clinical trial fully enrolled and interim results expected in mid-2025. Conkling will transition to an advisory role, ensuring a smooth transition and continued focus on clinical developments.

Spark’s Take on RFL Stock

According to Spark, TipRanks’ AI Analyst, RFL is a Neutral.

Rafael Holdings’ overall score reflects significant financial challenges, including declining revenues and negative profitability, which weigh heavily on its financial performance. While the technical analysis also indicates bearish signals, the recent merger with Cyclo Therapeutics provides a potential positive outlook by strengthening strategic assets and leadership. However, the valuation remains unattractive with a negative P/E ratio. Overall, the company’s current financial struggles and weak technical indicators are only partially offset by recent strategic moves, resulting in a moderate stock score.

To see Spark’s full report on RFL stock, click here.

More about Rafael Holdings

Rafael Holdings, Inc. is a company that holds interests in clinical and early-stage pharmaceutical companies, including its wholly-owned subsidiary, Cyclo Therapeutics, LLC. Cyclo Therapeutics is a clinical stage biotechnology company focused on developing Trappsol® Cyclo™, which is being evaluated for the treatment of Niemann-Pick Disease Type C1, a rare genetic disorder. Rafael Holdings also has majority equity interests in LipoMedix Pharmaceuticals Ltd., Cornerstone Pharmaceuticals, Inc., Rafael Medical Devices, LLC, and Day Three Labs, Inc.

YTD Price Performance: -5.11%

Average Trading Volume: 31,779

Technical Sentiment Signal: Strong Buy

Current Market Cap: $52.55M

For an in-depth examination of RFL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App